Acute Promyelocytic Leukemia Fab M3 — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute promyelocytic leukemia fab m3. 16 active patents protecting 2 drugs from 2+ originators. First major cliff: 2027. Daily refresh.

2
Approved drugs
16
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Promyelocytic Leukemia Fab M3

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Nippon Shinyaku Co., Ltd. 14 patents Bausch Health 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute promyelocytic leukemia fab m3. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
27
1
28
2
29
3
32
3
33
2
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytarabine
Cytarabine
 Nippon Shinyaku Co., Ltd. 14 51 — 2027-01-23
Retin-A
TRETINOIN
 Bausch Health 2 66 — 2038-08-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11324710 Retin-A method of use 70 2038-08-22
7850990 Cytarabine method of use 63 2027-01-23
10653656 Retin-A method of use 62 2038-08-22
7850990 Cytarabine other 58 2027-07-23
9271931 Cytarabine other 58 2027-07-23
8022279 Cytarabine method of use 58 2027-09-14
8022279 Cytarabine other 58 2028-03-14
8092828 Cytarabine method of use 58 2029-04-01
8092828 Cytarabine other 51 2029-10-01
10835492 Cytarabine method of use 45 2032-10-15

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9271931 Cytarabine formulation 43 2027-01-23
10166184 Cytarabine other 45 2033-04-15
10028912 Cytarabine other 45 2033-04-15
10835492 Cytarabine other 45 2033-04-15
10166184 Cytarabine method of use 45 2032-10-15
10835492 Cytarabine method of use 45 2032-10-15
10028912 Cytarabine method of use 45 2032-10-15
8092828 Cytarabine other 51 2029-10-01
8092828 Cytarabine method of use 58 2029-04-01
8022279 Cytarabine other 58 2028-03-14

Related